Table Info

Table 1.

The prevention of DCI after SAH

Parameters	Explanation
BP, after hemorrhage control	SBP 140–220 mmHg
Antihypertensive treatment	Nicardipine or labetalol
ICP control	Osmotic treatment and/or EVD
Osmotic treatment	Hypertonic saline or mannitol
Targeted hemoglobin level	More than 9 mg/dL
Intravenous solution treatment	Isotonic solutions are used for euvolemia
Oral nimodipine treatment	30 mg every 2 h (no risk of hypotension) Reduced to 30 mg every 4 h (risk of hypotension)
Avoided parameters	Hyperglycemia Hyperthermia Dehydration Hypoxia Hypocapnia

BP: blood pressure; SBP: systolic blood pressure; EVD: external ventricular drainage

Declarations

Author contributions

FE: planning, organization, writing, and editing. ATY, SEY, AD, CO: planning, writing, and editing. All authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Petridis AK, Kamp MA, Cornelius JF, Beez T, Beseoglu K, Turowski B, et al. Aneurysmal subarachnoid hemorrhage. Dtsch Arztebl Int. 2017;114:226–36. [DOI] [PubMed] [PMC]

Eisinger RS, Sorrentino ZA, Lucke-Wold B, Zhou S, Barlow B, Hoh B, et al. Severe headache trajectory following aneurysmal subarachnoid hemorrhage: the association with lower sodium levels. Brain Inj. 2022;36:579–85. [DOI] [PubMed]

Vergouwen MDI, Vermeulen M, van Gijn J, Rinkel GJE, Wijdicks EF, Muizelaar JP, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41:2391–5. [DOI] [PubMed]

Sarrafzadeh AS, Vajkoczy P, Bijlenga P, Schaller K. Monitoring in neurointensive care – the challenge to detect delayed cerebral ischemia in high-grade aneurysmal SAH. Front Neurol. 2014;5:134. [DOI] [PubMed] [PMC]

Schweizer TA, Al-Khindi T, MacDonald RL. Mini-Mental State Examination versus Montreal Cognitive Assessment: rapid assessment tools for cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. J Neurol Sci. 2012;316:137–40. [DOI] [PubMed]

Pu T, Zou W, Feng W, Zhang Y, Wang L, Wang H, et al. Persistent malfunction of glymphatic and meningeal lymphatic drainage in a mouse model of subarachnoid hemorrhage. Exp Neurobiol. 2019;28:104–18. [DOI] [PubMed] [PMC]

Suzuki H, Kanamaru H, Kawakita F, Asada R, Fujimoto M, Shiba M. Cerebrovascular pathophysiology of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Histol Histopathol. 2021;36:143–58. [DOI] [PubMed]

Liu JJ, Raskin JS, McFarlane R, Samatham R, Cetas JS. Subarachnoid hemorrhage pattern predicts acute cerebral blood flow response in the rat. Acta Neurochir Suppl. 2020;127:83–9. [DOI] [PubMed]

Motwani K, Dodd WS, Laurent D, Lucke-Wold B, Chalouhi N. Delayed cerebral ischemia: a look at the role of endothelial dysfunction, emerging endovascular management, and glymphatic clearance. Clin Neurol Neurosurg. 2022;218:107273. [DOI] [PubMed]

10.

Lominadze G, Lessen S, Keene A. Vasospasm risk in surgical ICU patients with grade I subarachnoid hemorrhage. Neurohospitalist. 2016;6:20–3. [DOI] [PubMed] [PMC]

11.

Veldeman M, Hollig A, Clusmann H, Stevanovic A, Rossaint R, Coburn M. Delayed cerebral ischaemia prevention and treatment after aneurysmal subarachnoid haemorrhage: a systematic review. Br J Anaesth. 2016;117:17–40. [DOI] [PubMed] [PMC]

12.

Chugh C, Agarwal H. Cerebral vasospasm and delayed cerebral ischemia: review of literature and the management approach. Neurol India. 2019;67:185–200. [DOI] [PubMed]

13.

Francoeur CL, Mayer SA. Management of delayed cerebral ischemia after subarachnoid hemorrhage. Crit Care. 2016;20:277. [DOI] [PubMed] [PMC]

14.

Budohoski KP, Guilfoyle M, Helmy A, Huuskonen T, Czosnyka M, Kirollos R, et al. The pathophysiology and treatment of delayed cerebral ischaemia following subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2014;85:1343–53. [DOI] [PubMed]

15.

Frontera JA, Claassen J, Schmidt JM, Wartenberg KE, Temes R, Connolly ES Jr, et al. Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified fisher scale. Neurosurgery. 2006;59:21–7. [DOI] [PubMed]

16.

Ikram A, Javaid MA, Ortega-Gutierrez S, Selim M, Kelangi S, Anwar SMH, et al. Delayed cerebral ischemia after subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2021;30:106064. [DOI] [PubMed]

17.

Lucke-Wold B, Hosaka K, Dodd W, Motwani K, Laurent D, Martinez M, et al. Interleukin-6: important mediator of vasospasm following subarachnoid hemorrhage. Curr Neurovasc Res. 2021;18:364–9. [DOI] [PubMed]

18.

Duan W, Pan Y, Wang C, Wang Y, Zhao X, Wang Y et al.; CNSR Investigators. Risk factors and clinical impact of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: analysis from the China National Stroke Registry. Neuroepidemiology. 2018;50:128–36. [DOI] [PubMed]

19.

Claassen J, Carhuapoma JR, Kreiter KT, Du EY, Connolly ES, Mayer SA. Global cerebral edema after subarachnoid hemorrhage: frequency, predictors, and impact on outcome. Stroke. 2002;33:1225–32. [DOI] [PubMed]

20.

Macdonald RL. History and definition of delayed cerebral ischemia. Acta Neurochir Suppl. 2013;115:3–7. [DOI] [PubMed]

21.

Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Chou SN, et al. Cerebral arterial spasm—a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308:619–24. [DOI] [PubMed]

22.

Amin-Hanjani S, Ogilvy CS, Barker FG II. Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis. Neurosurgery. 2004;54:326–35. [DOI] [PubMed]

23.

Al-Tamimi YZ, Bhargava D, Feltbower RG, Hall G, Goddard AJ, Quinn AC, et al. Lumbar drainage of cerebrospinal fluid after aneurysmal subarachnoid hemorrhage: a prospective, randomized, controlled trial (LUMAS). Stroke. 2012;43:677–82. [DOI] [PubMed]

24.

Park S, Yang N, Seo E. The effectiveness of lumbar cerebrospinal fluid drainage to reduce the cerebral vasospasm after surgical clipping for aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2015;57:167–73. [DOI] [PubMed] [PMC]

25.

Hasan D, Wijdicks EF, Vermeulen M. Hyponatremia is associated with cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. Ann Neurol. 1990;27:106–8. [DOI] [PubMed]

26.

Wijdicks EFM, Vermeulen M, Hijdra A, van Gijn J. Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms: is fluid restriction harmful? Ann Neurol. 1985;17:137–40. [DOI] [PubMed]

27.

Hasan D, Lindsay KW, Wijdicks EF, Murray GD, Brouwers PJ, Bakker WH, et al. Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage. Stroke. 1989;20:1156–61. [DOI] [PubMed]

28.

van den Bergh WM; MASH Study Group. Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid hemorrhage: the MASH Study. Stroke. 2006;37:2326–30. [DOI] [PubMed]

29.

Siironen J, Juvela S, Varis J, Porras M, Poussa K, Ilveskero S, et al. No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial. J Neurosurg. 2003;99:953–9. [DOI] [PubMed]

30.

Haley EC Jr, Kassell NF, Torner JC. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1993;78:537–47. [DOI] [PubMed]

31.

Dorhout Mees SM, Algra A, Vandertop WP, van Kooten F, Kuijsten HA, Boiten J et al.; MASH-2 Study Group. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet. 2012;380:44–9. [DOI] [PubMed] [PMC]

32.

Kirkpatrick PJ, Turner CL, Smith C, Hutchinson PJ, Murray GD; STASH Collaborators. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. Lancet Neurol. 2014;13:666–75. [DOI] [PubMed]

33.

Lennihan L, Mayer SA, Fink ME, Beckford A, Paik MC, Zhang H, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2000;31:383–91. [DOI] [PubMed]

34.

Zwienenberg-Lee M, Hartman J, Rudisill N, Madden LK, Smith K, Eskridge J, et al.; Balloon Prophylaxis for Aneurysmal Vasospasm (BPAV) Study Group. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke. 2008;39:1759–65. [DOI] [PubMed]

35.

Berman MF, Solomon RA, Mayer SA, Johnston SC, Yung PP. Impact of hospital-related factors on outcome after treatment of cerebral aneurysms. Stroke. 2003;34:2200–7. [DOI] [PubMed]

36.

Jost SC, Diringer MN, Zazulia AR, Videen TO, Aiyagari V, Grubb RL, et al. Effect of normal saline bolus on cerebral blood flow in regions with low baseline flow in patients with vasospasm following subarachnoid hemorrhage. J Neurosurg. 2005;103:25–30. [DOI] [PubMed]

37.

Muench E, Horn P, Bauhuf C, Roth H, Philipps M, Hermann P, et al. Effects of hypervolemia and hypertension on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation after subarachnoid hemorrhage. Crit Care Med. 2007;35:1844–51. [DOI] [PubMed]

38.

Kim DH, Joseph M, Ziadi S, Nates J, Dannenbaum M, Malkoff M. Increases in cardiac output can reverse flow deficits from vasospasm independent of blood pressure: a study using xenon computed tomographic measurement of cerebral blood flow. Neurosurgery. 2003;53:1044–52. [DOI] [PubMed]

39.

Darby JM, Yonas H, Marks EC, Durham S, Snyder RW, Nemoto EM. Acute cerebral blood flow response to dopamine-induced hypertension after subarachnoid hemorrhage. J Neurosurg. 1994;80:857–64. [DOI] [PubMed]

40.

Muehlschlegel S, Dunser MW, Gabrielli A, Wenzel V, Layon AJ. Arginine vasopressin as a supplementary vasopressor in refractory hypertensive, hypervolemic, hemodilutional therapy in subarachnoid hemorrhage. Neurocrit Care. 2007;6:3–10. [DOI] [PubMed]

41.

Reynolds MR, Buckley RT, Indrakanti SS, Turkmani AH, Oh G, Crobeddu E, et al. The safety of vasopressor-induced hypertension in subarachnoid hemorrhage patients with coexisting unruptured, unprotected intracranial aneurysms. J Neurosurg. 2015;123:862–71. [DOI] [PubMed]

42.

Mortimer AM, Steinfort B, Faulder K, Bradford C, Finfer S, Assaad N, et al. The detrimental clinical impact of severe angiographic vasospasm may be diminished by maximal medical therapy and intensive endovascular treatment. J Neurointerv Surg. 2015;7:881–7. [DOI] [PubMed]

43.

Treggiari MM; Participants in the International Multi-disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Hemodynamic management of subarachnoid hemorrhage. Neurocrit Care. 2011;15:329–35. [DOI] [PubMed]

44.

Lindegaard KF, Nornes H, Bakke SJ, Sorteberg W, Nakstad P. Cerebral vasospasm after subarachnoid haemorrhage investigated by means of transcranial Doppler ultrasound. Acta Neurochir Suppl (Wien). 1988;42:81–4. [DOI] [PubMed]

45.

Thomas JE, Rosenwasser RH, Armonda RA, Harrop J, Mitchell W, Galaria I. Safety of intrathecal sodium nitroprusside for the treatment and prevention of refractory cerebral vasospasm and ischemia in humans. Stroke. 1999;30:1409–16. [DOI] [PubMed]

46.

Meyer R, Deem S, Yanez ND, Souter M, Lam A, Treggiari MM. Current practices of triple-H prophylaxis and therapy in patients with subarachnoid hemorrhage. Neurocrit Care. 2011;14:24–36. [DOI] [PubMed]

47.

Soustiel JF, Shik V, Shreiber R, Tavor Y, Goldsher D. Basilar vasospasm diagnosis: investigation of a modified “Lindegaard index” based on imaging studies and blood velocity measurements of the basilar artery. Stroke. 2002;33:72–8. [DOI] [PubMed]

48.

Le Roux P, Menon DK, Citerio G, Vespa P, Bader MK, Brophy GM, et al. Consensus summary statement of the International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care: a statement for healthcare professionals from the Neurocritical Care Society and the European Society of Intensive Care Medicine. Neurocrit Care. 2014;21:1–26. [DOI] [PubMed]

49.

Stuart RM, Waziri A, Weintraub D, Schmidt MJ, Fernandez L, Helbok R, et al. Intracortical EEG for the detection of vasospasm in patients with poor-grade subarachnoid hemorrhage. Neurocrit Care. 2010;13:355–8. [DOI] [PubMed]

50.

Claassen J, Perotte A, Albers D, Kleinberg S, Schmidt JM, Tu B, et al. Nonconvulsive seizures after subarachnoid hemorrhage: multimodal detection and outcomes. Ann Neurol. 2013;74:53–64. [DOI] [PubMed] [PMC]

51.

Kimball MM, Velat GJ, Hoh BL; Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Critical care guidelines on the endovascular management of cerebral vasospasm. Neurocrit Care. 2011;15:336–41. [DOI] [PubMed]

52.

Hollingworth M, Chen PR, Goddard AJP, Coulthard A, Söderman M, Bulsara KR. Results of an international survey on the investigation and endovascular management of cerebral vasospasm and delayed cerebral ischemia. World Neurosurg. 2015;83:1120–6.e1. [DOI] [PubMed]

53.

Chalouhi N, Tjoumakaris S, Thakkar V, Theofanis T, Hammer C, Hasan D, et al. Endovascular management of cerebral vasospasm following aneurysm rupture: outcomes and predictors in 116 patients. Clin Neurol Neurosurg. 2014;118:26–31. [DOI] [PubMed]

54.

Firlik AD, Kaufmann AM, Jungreis CA, Yonas H. Effect of transluminal angioplasty on cerebral blood flow in the management of symptomatic vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg. 1997;86:830–9. [DOI] [PubMed]

55.

Rosenwasser RH, Armonda RA, Thomas JE, Benitez RP, Gannon PM, Harrop J. Therapeutic modalities for the management of cerebral vasospasm: timing of endovascular options. Neurosurgery. 1999;44:975–9. [DOI] [PubMed]

56.

McAuliffe W, Townsend M, Eskridge JM, Newell DW, Grady MS, Winn HR. Intracranial pressure changes induced during papaverine infusion for treatment of vasospasm. J Neurosurg. 1995;83:430–4. [DOI] [PubMed]

57.

Albanese E, Russo A, Quiroga M, Willis RN Jr, Mericle RA, Ulm AJ. Ultrahigh-dose intraarterial infusion of verapamil through an indwelling microcatheter for medically refractory severe vasospasm: initial experience. Clinical article. J Neurosurg. 2010;113:913–22. [DOI] [PubMed]

58.

Polat HB, Kanat A, Celiker FB, Tufekci A, Beyazal M, Ardic G, et al. Rationalization of using the MR diffusion imaging in B12 deficiency. Ann Indian Acad Neurol. 2020;23:72–7. [DOI] [PubMed] [PMC]

59.

Kanat A, Aydin MD, Bayram E, Kazdal H, Aydin N, Omeroglu M, et al. A new determinant of poor outcome after spontaneous subarachnoid hemorrhage: blood pH and the disruption of glossopharyngeal nerve–carotid body network: first experimental study. World Neurosurg. 2017;104:330–8. [DOI] [PubMed]

60.

Kanat A, Turkmenoglu O, Aydin MD, Yolas C, Aydin N, Gursan N, et al. Toward changing of the pathophysiologic basis of acute hydrocephalus after subarachnoid hemorrhage: a preliminary experimental study. World Neurosurg. 2013;80:390–5. [DOI] [PubMed]

61.

Yolas C, Ozdemir NG, Kanat A, Aydin MD, Keles P, Kepoglu U, et al. Uncovering a new cause of obstructive hydrocephalus following subarachnoid hemorrhage: choroidal artery vasospasm-related ependymal cell degeneration and aqueductal stenosis—first experimental study. World Neurosurg. 2016;90:484–91. [DOI] [PubMed]

62.

Findik H, Kanat A, Aydin MD, Cakir M, Ozmen SA, Okutucu M, et al. Describing a new mechanism of retinal detachment secondary to ophthalmic artery vasospasm following subarachnoid hemorrhage: an experimental study. J Neurol Surgery A Cent Eur Neurosurg. 2019;80:430–40. [DOI] [PubMed]

63.

Kurtz P, Helbok R, Ko SB, Claassen J, Schmidt JM, Fernandez L, et al. Fluid responsiveness and brain tissue oxygen augmentation after subarachnoid hemorrhage. Neurocrit Care. 2014;20:247–54. [DOI] [PubMed]

64.

Naidech A, Du Y, Kreiter KT, Parra A, Fitzsimmons BF, Lavine SD, et al. Dobutamine versus milrinone after subarachnoid hemorrhage. Neurosurgery. 2005;56:21–7. [DOI] [PubMed]

65.

Lannes M, Teitelbaum J, del Pilar Cortés M, Cardoso M, Angle M. Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol. Neurocrit Care. 2012;16:354–62. [DOI] [PubMed]

66.

Taccone FS, Citerio G; Participants in the International Multi-disciplinary Consensus Conference on Multimodality Monitoring. Advanced monitoring of systemic hemodynamics in critically ill patients with acute brain injury. Neurocrit Care. 2014;21:38–63. [DOI] [PubMed]

67.

Tseng MY, Al-Rawi PG, Pickard JD, Rasulo FA, Kirkpatrick PJ. Effect of hypertonic saline on cerebral blood flow in poor-grade patients with subarachnoid hemorrhage. Stroke. 2003;34:1389–96. [DOI] [PubMed]

68.

Seule MA, Muroi C, Mink S, Yonekawa Y, Keller E. Therapeutic hypothermia in patients with aneurysmal subarachnoid hemorrhage, refractory intracranial hypertension, or cerebral vasospasm. Neurosurgery. 2009;64:86–92. [DOI] [PubMed]

69.

Choi W, Kwon SC, Lee WJ, Weon YC, Choi B, Lee H, et al. Feasibility and safety of mild therapeutic hypothermia in poor-grade subarachnoid hemorrhage: prospective pilot study. J Korean Med Sci. 2017;32:1337–44. [DOI] [PubMed] [PMC]

70.

Appelboom G, Strozyk D, Hwang BY, Prowda J, Badjatia N, Helbok R, et al. Bedside use of a dual aortic balloon occlusion for the treatment of cerebral vasospasm. Neurocrit Care. 2010;13:385–8. [DOI] [PubMed]

71.

Ehtisham A, Taylor S, Bayless L, Samuels OB, Klein MW, Janzen JM. Use of intrathecal nicardipine for aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm. South Med J. 2009;102:150–3. [DOI] [PubMed]

72.

Lazaridis C, Pradilla G, Nyquist PA, Tamargo RJ. Intra-aortic balloon pump counterpulsation in the setting of subarachnoid hemorrhage, cerebral vasospasm, and neurogenic stress cardiomyopathy. Case report and review of the literature. Neurocrit Care. 2010;13:101–8. [DOI] [PubMed]